Abstract
Safety and Efficacy of Ibrutinib Maintenance (I-M) Following Frontline Induction in Mantle Cell Lymphoma (MCL) with Sequential Assessment of Changes in NGS-MRD
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have